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Chemokine receptor CCR5 and the mu opioid receptor (MOR) undergo receptor
dimerization in the membranes of neuronal cells. CCR5 is a co-receptor for the human
immunodeficiency virus's (HIV) entry into host cells and is therefore a potential target of small
molecule antagonists for therapeutic purposes. Activation of MOR is believed to both increase
CCR5 expression levels and increase HIV viral entry into neuronal cells by dimerizing with
CCR5. It is therefore of interest to develop chemical probes that target the CCR5-MOR
interaction.
A bivalent ligand containing both CCR5 and MOR pharmacophores was previously
designed and synthesized to study the CCR-MOR heterodimer and its relavence to NeuroAIDS.
In this work, two more bivalent ligands with structural modifications in spacer length were

designed and synthesized along with a number of control compounds. The structure-activity
relationships of these compounds were studied in radio-ligand binding assays and cell-based
functional assays. Furthermore, the original bivalent ligand and the two new ligands were
subjected to conformational analysis.
In conclusion, bivalent ligands were synthesized to target the putative CCR5-MOR
heterodimer, and these molecules were subjected to in vitro and in silico studies. The two new
bivalent molecules bound to the MOR with an activity similar to that of naltrexone, an MOR
antagonist, while they bound to CCR5 with lower affinity compared to maraviroc, a CCR5
antagonist, indicating that further structural modification to the CCR5 portion of the bivalent
ligand is necessary. Also, further work is underway to verify that the two novel bivalent
compounds can indeed recognize to the CCR5-MOR heterodimer with reasonable potency.

1. Introduction

1.1 Chemokine Receptor CCR5

1.1.1 Function of Chemokines and Chemokine Receptors
Chemokines, or chemotactic cytokines, are a small group of signal proteins that act as mediators
in the process of inflammation.1–6 When inflammation is induced in living tissue, mediators are released
into the blood-stream; these mediators (i.e., cytokines) then bind to proteins on the membranes of
leukocytes, or white blood cells, which are recruited to the site of inflammation in order to protect the
body from unwanted bacteria.1–3 Chemokine receptors are among several proteins on the surface of
leukocyte cell membranes that interact with the mediators of inflammation.3
There are about 50 known and classified chemokines.3,6 Four families of chemokines exist and
they are grouped based on the conserved cysteine residues found at the N-terminal of the peptides: CC
chemokine, C chemokine, CXC chemokine and CX3C chemokine.3 In the CC family, the cysteine
residues are adjacent to each other.3 In the C family, on the other hand, one of the cysteine residues is
missing.3 For the CXC and CX3C families, the two cysteines are separated by one and three variable
residues, respectively.3 Most of the known chemokines fall into the CC and CXC families and to date
there are only 18 known chemokine receptors.3

1.1.2 Chemokine Receptor Type CCR5 and GPCRs
Chemokine receptors fall into a superfamily of membranous proteins called G protein-coupled
receptors (GPCR).3–6 These proteins are characterized by their canonical seven transmembrane (TM)
helices which bind to heterotrimeric G proteins to mediate responses from outside signal molecules.
The GPCR superfamily of proteins includes 791 genes encoding for six different receptor subtypes,

1

most of which belong to the rhodopsin-like receptor subtype, or the class A subtype.3 Chemokine
receptors are all within the class A GPCR subtype.3 Chemokine receptors are classified based upon
which chemokines bind to them; thus there are CC, CXC, XC and CX3C receptors.3 Also, many of the
chemokine receptors are promiscuous and bind to different chemokines within a chemokine family.1–5
For example, a CC receptor can bind to many different CC chemokines. This allows for redundancy of
response, given that many different chemokines within a family can elicit the same response at the
same receptor.

Figure 1. A canonical representation of a GPCR.7
When a chemokine binds to a chemokine receptor, it starts an activation cycle that is
characteristic for all GPCRs.3 That is, when a resting chemokine receptor is activated by an agonist, the
bound inactive heterotrimeric G protein, which is composed of guanosine diphosphate (GDP) bound
2

Gα and Gβγ subunits, is converted to an active G protein.8–14 This protein becomes active by
exchanging GDP for guanosine triphosphate (GTP), whereupon the Gα and Gβγ subunits dissociate
from each other.11, 12, 14 These subunits then go on to activate or inhibit different downstream signaling
pathways through the recruitment of various second-messenger proteins such as adenylyl cyclase and
phospholipase-C.11, 12 These subunits remain active until the GTP is hydrolyzed back to GDP,
whereupon the Gα and Gβγ subunits re-associate with each other and travel back to the resting-state
GPCR.11, 12, 14
Looking at agonist-bound crystal structures of GPCRs, several structural changes between
activated and unactivated GPCRs are noteworthy.9, 10, 15 For instance, there are several changes in the
transmembrane helices upon agonist binding.9, 10 These include an outward movement of TM6 and a
rearrangement between TM5 and TM7.9, 10 For particular amino acid residues, there is a disruption of a
conserved ionic lock between aspartate/glutamate and arginine of the DRY sequence and the movement
of tryptophan6.48 from TM7 to TM5, both of which allow for the facilitation of the receptor to a more
active state.10 However, it should be noted that these structural changes have not been observed in every
GPCR to date.
Chemokine receptor type CCR5 (CCR5) is a chemokine receptor that undergoes such
conformational changes when it binds to chemokines.8, 16, 17 CCR5 is expressed on leukocytes and is
activated by several chemokines, including, but not limited to, macrophage inflammatory protein-1α
(MIP-1α), MIP-1β and regulated upon activation normally T-cell expressed and secreted (RANTES).8
Activation of CCR5 by these chemokines leads to several signaling cascades that are characteristic of
many GPCRs.

1.1.3 CCR5 Downstream Effects and Regulation
CCR5 induces several downstream effects upon agonist binding.16–18 These include intracellular
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Ca2+ release from the endoplasmic reticulum (ER), activating MAP kinases and inhibiting adenylyl
cyclase.16 CCR5 is also promiscuous for the types of Gα subunits it activates, as it activates both Gαi
and Gαq.17 Because CCR5 couples to two different G proteins, it allows CCR5 to activate more than
one signaling pathway.17 For the pathway involving Gαi, the Gα subunit inhibits adenylyl cyclase.17
This reduces the production of cAMP from ATP. For the pathway involving Gαq, phospholipase C
(PLC) becomes activate and produces diacyl glycerol (DAG) and inositol triphosphate (IP3) by
hydrolyzing phosphatidylinositol 4,5-biphosphate (PIP2).17 DAG goes on to activate protein kinase C
(PKC), whereas IP3 activates calcium channels on the ER and causes the amount of intracellular
calcium to increase.17 The Gβγ subunit also plays a roll in downstream signaling by activating PLC,
which, as already mentioned, increases the production of intracellular calcium.17

Figure 2. The CCR5 signaling cascade leads to multiple downstream effects.
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GPCRs such as CCR5 are regulated by a variety of mechanisms; these include desensitization
of the receptor, internalization of the receptor and recycling/degradation of the receptor.19, 20
Desensitization of the receptor reduces its response to external stimuli, whereas internalization and
recycling/degradation of the receptor reduce the amount of receptors present on the cell's membrane.19,
20

Repeated activation of the receptor by agonists leads to desensitization through the phosphorylation

of the GPCR's C-terminus; the protein becomes desensitized by the phosphorylation of four serine
residues – S336, S337, S342 and S349 – by G protein-coupled receptor kinases (GRKs).20 For the
process of internalization and recycling/degradation of the receptor, the phosphorylated serine residues
increase the binding affinity of GPCRs for β-arrestin.20 When β-arrestin binds to a GPCR, it blocks G
proteins from binding to it, thereby eliminating the GPCR's downstream signaling pathways.20 βarrestin can then complex with adaptor complex 2 (AP2) and clathrin.20 This complex causes the GPCR
to internalize by endocytocis, whereupon it is either degraded by lysosomal proteins or recycled back to
the membrane.20 Also, β-arrestins can activate several cascades by activating mitogen-activated protein
kinases (MAPKs) and non-receptor tyrosine kinases (nRTKs).19, 20 Furthermore, a GPCR can be
desensitized through the binding of a certain ligand which reduces the GPCR's affinity for other
ligands (this ligand varies depending on the GPCR to which it binds).19

1.1.4 GPCRs as Drug Targets and CCR5 in HIV-Associated Diseases
GPCRs are among the most targeted proteins for therapeutic purposes.21 In fact, more than 30%
of all drugs designed in the last five years target GPCRs.22, 23 One of the disease states associated with
GPCRs is cancer.24, 25 When a gene encoding for a GPCR has been mutated in such a way so as to
produce a constitutively active protein, very often the signaling pathways downstream of that GPCR
remain active.24, 25 This leads to the growth and differentiation of cells in which the GPCR is expressed.
CCR5 is also associated with breasts cancer, ovarian cancer and prostate cancer.25 – 30
5

CCR5 is also associated with the human immunodeficiency virus (HIV).31 In fact, CCR5 is
among the most targeted proteins in HIV therapeutics.31 This is because CCR5 acts as a vital coreceptor in HIV invasion into host cells.31–33 Although CCR5 is predominantly expressed on leukocytes,
in particular helper-T cells, it is also expressed on microglia and astroglia, and the infection of these
cells contributes to the degradation of neurons..31 CCR5's association with HIV-invasion in host cells is
described in more detail below this section.

1.1.5 CCR5's Association with HIV/AIDS
HIV causes the destruction of lymphocytes expressing cluster of differentiation 4 (CD4)
membranous proteins.31 This leads to an immunocompromised disease known as acquired
immunodeficiency syndrome (AIDS).31 In particular, this disease is most prevalent in developing
countries in sub-Saharan Africa, and most mortalities from AIDS come from this region.27 About 1.6
million people died from AIDS in 2012 according to the Center for Disease Control, and more than 2
million are infected per year on average.31 The virus consists of a single strand of RNA necessary to
encode viral enzymatic and structural proteins.31
The virus invades host cells by using a viral envelop protein (Env) consisting of three
glycoprotein subunits that bind to and interact with CD4.31 This glycoprotein consists of gp41 and
gp120 subunits.31 A conformational change in the gp120 subunit upon CD4 binding allows it to interact
with CCR5, which acts as a co-receptor in HIV viral entry.31 Once this three-protein complex is formed
between CD4, gp120 and CCR5, another conformational change occurs in the Env protein that allows
gp41 to insert itself into the host cell's membrane.31 This further facilitates viral entry into host cells.
However, although CCR5 helps the HIV virus invade host cells, receptor CD4 is the main receptor of
HIV.
The importance of CCR5 in HIV infection is demonstrated by the increased resistance that
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people with homozygous CCR5 recessive alleles have to HIV viral invasion.35, 36 That is, if an
individual has mutations in both CCR5-encoding genes, then HIV cannot use CCR5 as a co-receptor to
invade host cells. Mutations to CCR5 prevent the gp120 subunit of the Env protein from binding to it
and facilitating viral entry.

Figure 3. CCR5 and CXCR4 act as co-receptors in helping facilitate viral entry into host cells.37

1.1.6 Small molecules targeting CCR5
Pharmaceutical companies have been trying to develop small-molecule antagonists that target
CCR5, mostly because of its involvement in HIV host cell invasion.39–42 These efforts have led to the
approval of maraviroc (1) by the FDA to treat retroviral infections.39–41 Maraviroc was developed by
Pfizer from a high-throughput screening (HTS) hit in the early 2000's.39–41 The initial compound showed
a high affinity for CCR5 (Ki = 4 nM) but did not produce any antiretroviral activity.39, 40 Therefore, the
compound was modified using structure-activity relationship (SAR) techniques, and this led to a
7

molecule, maraviroc, that had an IC50 = 2 nM for the CCR5 receptor. In fact, clinical studies indicated
that two daily doses of 25 mg maraviroc were more effective at slowing the progression of HIV-1 host
cell invasion than the current leading anti-HIV-1 drug at the time.41

Table 1. Small molecule CCR5 antagonists
Name

Structure

Status
F

N
N

Maraviroc

N

N

F

HN

FDA-approved

O

1
N

O
N

N
N

N

Vicriviroc

Terminated

O
F3C

2
O

Aplaviroc

OH

N

O

Terminated
NH

O

N

3
H
N

TAK-779

O

N
O

4

8

Modified form in Phase
II Clinical Trials

Two other anti-HIV-1 drugs that showed very good antagonism for the CCR5 receptor were
vicriviroc (2) and aplaviroc (3).41 However, both these drugs were discontinued during Phase III
clinical trials because vicriviroc had poor bioavailability and aplaviroc showed severe hepatotoxicity.41,
43

To date, maraviroc is considered the most effective drug for inhibiting the progression of HIV

through antagonism of CCR5.44 However, Schering-Plough has reported the development of a secondgeneration CCR5 antagonist known as SCH532706.44 As of right now, SCH532706 is in Phase III
clinical trials, and the molecule shows both high anti-HIV-1 activity and good bioavailability.44
Before the development of maraviroc and other second-generation CCR5 antagonists, TAK-779
(4), the first known CCR5 antagonist, was reported by Takeda Chemicals in 1999.45 The molecule was
shown to inhibit HIV-1 entry with an IC50 = 3.7 nM.45 The molecule was also shown to have a very high
affinity for CCR5 in a radioligand binding assay (Ki = 1.4 nM).45 However, the molecule's development
was discontinued because of both poor oral bioavailability and toxicity issues, although modification to
improve oral bioavailability led to another CCR5 antagonist which is currently in phase II clinical
trials.44

1.2 The Mu Opioid Receptor

1.2.1 Opioid Receptors
Opioid receptors are the site of action for morphine and its derivatives.46 The name “opioid”
comes from the fact that morphine, the first known exogenous agonist of this class of receptors, was
isolated from opium poppy extracts.46 Opioid receptors, like chemokine receptors, are GPCRs.46 To date
there are four known opioid receptors that have been crystallized: δ opioid receptor (DOR), κ opioid
receptor (KOR), µ opioid receptor (MOR) and nociception/orphanin opioid receptor (NOR).47–50 Two of
these receptors – KOR and MOR – were named according to the opiates to which they bound:
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morphine and ketocyclazocine, respectively.47, 49 There are also small endogenous peptides that bind to
opiate receptors; they include enkephalins and dynorphins.51–55
When opiates bind to their MOR, they elicit analgesic and anti-diarrheal effects.51, 52 This gives
them a high therapeutical potential, especially in settings requiring fast-acting pain-relief. However,
although opiates elicit analgesic and anti-diarrheal effects upon binding to their receptors and produce
numerous therapeutic results, there are certain unwanted side-effects when taking them.56–59 For
instance, the molecule morphine has a high potential for abuse because of its addictive nature.56–59 Much
of the work that has been done modifying opiates, therefore, has focused on reducing this addictive
potential.60 Also, it has been discovered that while the three traditional opioid receptors – DOR, KOR
and MOR – each produce analgesic effects, the neural response that each receptor controls is
different.52 DOR affects anxiety and depressive behaviors, KOR produces dysphoria and MOR control
euphoric feelings.52

1.2.2 Mu Opioid Receptor Structure and Downstream Signaling
As mentioned before, opioid receptors are included in the GPCR superfamily.61 Thus, the mu
opioid receptor shares many structural features with other common GPCRs, most importantly the seven
TM helices. Of note, MOR has a β-hairpin in extracellular loop (EL) 2.61
Because MOR is a GPCR, it shares many of the same signaling mechanisms as CCR5, such as
the activation of a heterotrimeric G protein.61 However, because it is coupled to a different G protein
(i.e., Gαi/o) from CCR5, it causes the activation of different downstream signaling pathways upon
agonist binding.61 For instance, Gαi inhibits adenylyl cyclase and activates K+ channels, whereas Gαo
inhibits Ca2+ channels (and thus causes the concentration of intracellular calcium to decrease).61
However, because the Gβγ subunit activates PLC and thus increases the concentration of intracellular
calcium, agonist binding to MOR can also cause an effect opposite from that of Gαo activation. This
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creates a negative feedback loop that allows for fine-tuning of downstream signaling.
As with the CCR5 receptor, MOR activity is also regulated: desensitization and protein-based
trafficking also occur so as to limit the amount of receptor activity on a cell's membrane.61
Phosphorylation of the serine residues located at the protein's C-terminus cause it to become
desensitized to external stimuli, and this also leads to β-arrestin recruitment and receptor
internalization.61 However, it should be mentioned that morphine does not cause receptor
phosphorylation at high levels.61 Rather, endogenous ligands such as etorphine are responsible for such
effects.55

1.2.3 Opioid Addiction and Its Effects on HIV/AIDS Infected Individuals
While opiates are effective at reducing pain, they increase the risk of drug-based addiction and
abuse in individual patients.56–59 This abuse is particularly dangerous in patients that are infected with
HIV, as it has been shown that the rate of HIV-1 progression spikes in opiate-addicted patients with
AIDS.62–68 This HIV-1 progression coupled with opiate addiction increases the likelihood of HIVassociated neurocognitive disorders (HANDs) and neurological complications of AIDS (neuroAIDS).62,
66

Thus, the use of opiates by HIV-infected patients appears to have a complimentary effect on the rate

of viral proliferation.65–67
Studies have shown that MOR is responsible for the addictive properties of morphine.58, 59 In
MOR-knockout mice, morphine's addictive properties were abolished.58 Also, MOR-knockout mice are
less prone to develop addictions to other drugs such as nicotine and alcohol, indicating the importance
of the MOR in influencing general addiction.58, 59 However, despite their involvement in producing and
prolonging addiction, MOR agonists such as morphine are still used to treat pain. In fact, many novel
drugs used to treat pain are modified analogs of morphine.60 As such, most of the new drug-design
projects involving opiates focus not only on improving the selectivity and potency of MOR agonists,
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but also making them less addictive. Opiate addiction is still a problem in general society, however, in
particular among HIV patients.62–68

1.2.4 Addiction in NeuroAIDS
In HIV-infected patients, the progression of AIDS is accelerated by the use of opiates.69–71 The
central nervous system (CNS) in particular seems to be the most affected region of AIDS progression in
opiate-addicted individuals.72, 73 This is because of the fact that both CCR5 and MOR are expressed on
the glial cells (astroglia and microglia) of the CNS and MOR can heterodimerize with CCR5 when
activated by an opiate.69–71 In fact, MOR has been shown to effect immunomodulation by acting as a
chemokine and potentiating the downstream signaling pathways of chemokine receptors.74, 75 Also,
activation of MOR has been shown to increase the expression levels of CCR5, resulting in more coreceptors for HIV.76, 77
HIV does not directly degrade neurons of the CNS, but instead infects the microglia and
astroglia surrounding them.73, 76 This is because CCR5 is more prevalent on glial cells than on
neurons.76 When HIV-1 infects glial cells, it not only destroys such cells when new virions are released
into the external environment; it also releases byproducts, such as viral proteins and chemokines, that
result in degeneration of neuronal cells.76 The proximity of glial cells to neurons result in the excreted
toxins damaging neurons, which leads to inflammation.76, 77 Opiates potentiate the infection of HIV in
microglia through MOR dimerizing with CCR5, which makes the latter protein more susceptible to
HIV-1 attachment.69–71

1.2.5 Mu Opioid Receptor Ligands: Agonists and Antagonists.
There are both known exogenous and endogenous agonists that bind to MOR.78, 79 While the
former are small molecules derived from morphine (5), the latter are peptides.78 Because of morphine's
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unwanted side-effects, the development of new MOR agonists that have reduced addictive potentials
has been explored.79 The table below shows some of the peptidic and non-peptidic agonists of MOR.
One of the peptidic agonists, DAMGO (7), is a synthetic peptide based off of an enkephalin, and it is
highly selective for MOR over the other opioid receptors.78

Table 2. Three MOR agonists.
Structure
KOR Ki
(nM)

Name

DOR Ki
(nM)

MOR Ki
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Along with the agonists, there have been several antagonists developed to treat morphine and
general opiate addiction (N.B., see table below).80–83 These, like the agonists, also include both small
molecules and synthetic peptides.80–83 Both naloxone (8) and naltrexone (9) are non-selective
antagonists for all three traditional opioid receptors (i.e., DOR, KOR and MOR).80
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Table 3. Six MOR antagonists.
Structure
KOR Ki (nM)

Name

DOR Ki (nM)

MOR Ki (nM)
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To improve selectivity for MOR over the other two opioid receptors, β-FNA (10) was
synthesized.83 While β-FNA binds to all three receptors, it only binds to MOR irreversibly.83 Notice,
however, that the only difference between β-FNA and naltrexone is the group attached to the C-ring of
the morphanin core. This fact supports the “message-address” concept proposed by Portoghese et al.84
This concept is based on the premise that the morphanin scaffold has two main parts: 1) the morphanin
core, or the “address” portion of the molecule, that is active at all opioid receptors and 2) the “message”
portion of the molecule, which is located off of the C-ring and helps determine receptor selectivity for
the molecule. In other words, selectivity for a particular receptor can be altered merely by changing the
group (i.e., the “message” portion) attached to the C-ring of a morphine-derived molecule. This is why
β-FNA is selective for MOR whereas naltrexone is not despite having similar core structures.83, 84 The
molecule clocinnamox (11) was also designed using the message-address concept in order to improve
selectivity for MOR over the other two traditional opioid receptors.81 Cyprodime (12) has the highest
selectivity for MOR among the molecules presented here.80 This is because removing the dihydrofuran
ring from a morphanin core reduces its affinities for KOR and DOR but not MOR.80 Finally, CTAP
(13), a cyclic peptide, has the greatest affinity for the MOR receptor among the molecules listed in the
table with a Ki in the low nanomolar range.82
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Figure 4. β-FNA (10) illustrates the message-address concept for opioid receptor selectivity.

1.3 GPCR Dimerization
It was thought that all GPCRs acted in a monomeric fashion in which the protein's activation
was dependent only upon the binding of a single ligand. However, evidence was discovered indicating
that GPCRs could dimerize with one another and sometimes form oligomeric complexes.85, 86 It was
also discovered that the binding of one ligand to a GPCR could prevent another GPCR from interacting
with its ligand.85 This interaction, termed “cross-talk,” illustrates the ability of an activated GPCR to
affect the activity of another GPCR for a ligand through dimerization.85, 86 Furthermore, it has been
demonstrated that receptor cross-talk can either enhance or decrease the activity of an adjacent,
dimerized receptor for its ligand.85–89
Advanced techniques have been developed for detecting the dimerization of two GPCRs,
including bioluminescence resonance energy transfer (BRET), fluorescence resonance energy transfer
(FRET), and advanced crystallization techniques.91–95 For FRET, two proteins are tagged with two
different fluorescent proteins.91, 95 If the proteins dimerize, then when one of the proteins (i.e., the donor
chromophore) is stimulated by fluorescent light it will transfer energy of a particular excitation
wavelength to the adjacent protein (i.e., the acceptor chromophore), causing it to also emit light of a
particular wavelength.91, 95 It is important to note that the acceptor chromophore will only emit light if
the donor chromophore has dimerized with it. BRET also uses a similar technique, except the donor
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chromophore is coupled with a bioluminescent luciferase enzyme and therefore doesn't need to be
stimulated by light from an external source.91, 95 Either way, both techniques are ideal for detecting the
presence of protein dimers using fluorescent light.91, 95 A more modern technique using GPCR
crystallization coupled with atomic-force microscopy is also a good way of detecting GPCR
dimerization.92
It is important to mention that GPCR dimerization has an important function on receptor
activity and signaling. As mentioned beforehand, GPCR dimerization can either enhance the affinity of
a receptor for its ligand or decrease a receptor's affinity for its ligand. The former scenario, termed
positive cooperativity, leads to a receptor with greater signaling and function, whereas the latter
situation, termed negative cooperativity, leads to a receptor with decreased signaling capabilities.86

Figure 5. Positive and negative cooperativity in GPCR dimerization.
1.3.1 Mu Opioid Receptor Dimerization
There have been multiple studies illustrating the ability of MOR to dimerize with another MOR
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and other GPCR types.96–99 MOR has been shown to dimerize with KOR, DOR, NOR, CCR5 and
cannabinoid receptors.96–100 Interestingly, when MOR is dimerized with another receptor, it is able to
activate signaling pathways that it cannot activate on its own.99 For example, when not dimerized with
another opioid receptor, neither MOR nor DOR can couple with the Gαq/11 G protein.99 However, when
coupled together, the MOR-DOR complex activates the Gαq/11 signaling pathway quite readily.99 This
suggests that certain heterodimers can activate signal pathways that the monomers cannot activate
themselves. Dimerization may also enhance or inhibit the rate of receptor desensitization and
internalization, as evidenced by studies involving the MOR-NOR heterodimer.101

1.3.2 Bivalent Ligands Targeting GPCR Heterodimers.
Bivalent compounds are necessary probes for studying the interaction between two distinct
monomers that form a dimer.102–104 Bivalent compounds are molecules that contain two distinct
pharmacophores, and they can either be classified as homobivalent or heterobivalent depending on
whether or not they contain the same or different pharmacophores.102 In studies involving the
dimerization of the same two protein types (homodimerization), a homobivalent molecule is necessary
to analyze the interaction; the converse is true for studies involving the dimerization of two dissimilar
protein types (heterodimerization).103 By targeting a dimer of GPCRs using a bivalent compound, new
pharmacological profiles can be obtained revealing information particular to that dimer.102, 104 Also,
bivalent compounds can lead to higher affinity and higher selectivity for the target in question.102–104
The two pharmacophores in a bivalent compound are often attached to each other – or bridged –
by a linker of carbon atoms.102–104 This linker both allows each pharmacophore to interact with its
receptor individually and also enables both pharmacophores to bind at a similar time. Researchers have
anticipated that the average distance between two GPCR dimers in anywhere from 27 Å to 32 Å.
Therefore, a linker should be somewhere within that range.103
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There are numerous linkers targeting MOR heterodimers that have been synthesized to date.105108

They include an MOR agonist, oxymorphone, and a type 2 cholecystokine (CCK2) receptor

antagonist being synthesized across a linker in order to determine if the MOR and CCK2 associate in
vivo (14).105 They also include compound 15, a MOR-KOR binding compound that contained the
MOR antagonist naltrexone and the KOR antagonist 5'-GNTI.106
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Finally, there was a series of compounds similar to 16 that contained both pharmacophores for
DOR and MOR.107 This series was made to assess the functional role of the MOR-DOR heterodimer in
analgesia.107 Portoghese et al. wanted to see whether or not a bivalent analgesic compound could be
designed that mitigated the deleterious, addictive side-effects of morphine.107 16 was comprised of an
MOR agonist, oxymorphone, and a selective DOR antagonist, naltridole. The two pharmacophores
were separated by a 21-atom spacer with a maximum length of 25.4 Å. It was found that this molecule
was 50-fold more potent than morphine without producing tolerance or dependence side-effects, which
also illustrated the importance of DOR in potentiating the activity of MOR.107
However, because molecule 16 was not selective for the MOR-DOR heterodimer over the
MOR-MOR and DOR-DOR homodimers, Harvey et al. developed two fined-tuned MOR-DOR
bivalent compounds – 17 and 18 – a that were very selective for their intended target.108 The reason
they did this was because 16 could also interact with the MOR-MOR and DOR-DOR homodimers with
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similar affinity to the MOR-DOR heterodimer.108 In order to solve this problem and fine-tune their
molecule, they constructed 17, a molecule containing the MOR agonist oxymorphone and a low
affinity DOR antagonist, ENTI, and 18, a molecule containing the MOR antagonist naltrexone and a
low affinity DOR agonist, DMSNC80. These molecules had reduced affinity for the DOR-DOR and
MOR-MOR homodimers.108 Of note, both compounds synergistically raised the binding affinity for the
DOR pharmacophore when the binding assays were conducted using membranes composed of MORDOR relative to assays conducted using DOR alone membranes.108 The concept of fine-tuning the
ability of bivalent ligands to bind to a particular dimer using high and low affinity pharmacophores is
an important aspect of drug design using bivalent compounds.

2. Bivalent Ligands Targeting the Putative CCR5-MOR Heterodimer

2.1 Project Design
The effects of human immunodeficiency virus (HIV)-1 has been shown to be potentiated by the
abuse of various drugs, including alcohol, opioids and cocaine.62, 64-67 In fact, many cases of HIV
infection can be attributed to the use of contaminated needles.109 The abuse of certain drugs – opioids in
particular – has been associated with the mu opioid receptor (MOR) due to the ability of those drugs to
bind to and agonize MOR. Furthermore, the binding of opioids to MOR have been shown to change
the normal response of the immune system, a condition called immunomodulation, due to the ability of
MOR to regulate chemokine receptors; this condition, in turn, has been shown to produce negative
immunological effects due to the inability of modulated chemokine receptors to respond to infections.62,
110

Given that HIV progression is associated with the immune system and the functioning of

lymphocytes, changes in the immune system can result in the potentiation of HIV.62, 68
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Chemokine receptor CCR5, a G-protein coupled receptor (GPCR), is expressed on many cell
types, including lymphocytes and neuronal cells.32, 33, 111, 112 CCR5 has been shown to act as a co-receptor
in HIV cellular invasion. It has also been demonstrated that the inhibition of CCR5 mitigates HIV viral
entry into lymphatic cells and cells of the central nervous system (CNS).111-113 Maraviroc, a synthetic
CCR5 antagonist, was developed by Pfizer to combat the invasion of HIV into lymphatic cells in the
mid 2000's.113 In combination with different antiretroviral therapies, maraviroc has been shown to
inhibit the progression of HIV-1 infection. However, other health complications, such as HIVassociated neurocognitive disorders (HANDS), effect half of AIDS patients and are not mitigated by
maraviroc.114, 115 These patients are characterized by behavioral abnormalities such as reduced cognition
and motor control, health effects resulting from the invasion of HIV into cells of the CNS, in particular
microglia and astrocytes.114, 115 Since microglia defends primary neuronal cells from infection and
astrocytes are responsible for the delivery of nutrients into the brain, complications can result from the
destruction or induced inactivity of these cell types.76 The immunocompromised state of these cells by
HIV-1 infection results in a condition known as neuroAIDS.114, 115
The increased risk of HIV-1 infection in cells of the CNS has been linked to the stimulation of
MOR by opiates.62, 64–66, 75, 77 This is because, once agonized by an opioid, MOR may produce synergistic
interactions with CCR5.75, 77 An example of this is how activation of MOR by opioids up-regulates the
expression of CCR5 in cells, which in turn promotes HIV-1 infection via the virus using CCR5 for viral
entry.77 Opiates can also indirectly damage primary neuronal cells by causing inflammation in microglia
and astrocytes.63, 116 The type and extent of neuronal injury to different neurons by HIV-1 infection has
also been correlated with the amount of MOR expressed on those neuronal cell types.116, 117
Verification of the synergism between the MOR and CCR5 has been demonstrated by the ability
of the receptors to heterodimerize and undergo receptor crosstalk.118, 119 Since this crosstalk was
discovered to take place in lymphocytes, it has been hypothesized that it also takes place in neurons and
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therefore may lead to the progression of neuroAIDS.118 Recently, a bivalent compound (18) was
synthesized that contained maraviroc, a CCR5 antagonist, and naltrexone (N.B., converted to 6βnaltrexamine), an MOR antagonist, each separated by a linker (Figure 6).120 The purpose of this
bivalent compound was to study the pharmacological profile of CCR5-MOR heterodimerization and its
relationship with neuroAIDS.120 It is worthy to note that this bivalent compound is the first compound
to target the putative MOR-CCR5 heterodimer and is therefore considered a novel chemical probe in
the study of neuroAIDS and HANDS.120
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Figure 6. The first reported bivalent compound targeting the CCR5-MOR heterodimer.24

The purpose of synthesizing the bivalent compound (18) was to design a molecule that could
antagonize both the MOR and CCR5 receptors simultaneously, as shown in Figure 7. Both maraviroc
and naltrexone were selected based on their binding affinities for CCR5 and MOR (respectively) and
their pharmacological profiles.120 It should be noted that both molecules had to be functionalized with
an amino group in order to initiate linker attachment via amide coupling.120 The structure of the linker
and its attachment to maraviroc and 6β-naltrexamine were based on the work of Daniels et al. with
various opioid receptors and their antagonists.107 In their research, they found that using a 21-atom
spacer was optimal in studies involving opioid receptor heterodimerization, and therefore 18 was
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synthesized in the study of CCR5-MOR heterodimerization carried the same spacer length.107, 120
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Figure 7. Strategy for designing a bivalent compound to target the CCR5-MOR heterodimer.
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From molecular modeling studies involving the docking of maraviroc to a homology model of
receptor CCR5, it was hypothesized that the phenyl ring could accommodate either a 3- or 4-position
linker (Figure 8).121 Therefore, testing a bivalent compound involving a 3-position linker was necessary
to determine whether or not such a compound could produce better activity at the CCR5 receptor
relative to the original 4-position compound (18).

Figure 8. Maraviroc bound to a homology model of receptor CCR5.121

After 18 was synthesized and tested in biological assays, another novel bivalent compound (19)
utilizing maraviroc and 6β-naltrexamine pharmacophores was also synthesized and tested in biological
25

assays, only this time the amine group was altered from the 4-position to the 3-position of maraviroc
(Figure 9). This was done to allow for fine-tuning of the bivalent compound to the CCR5-MOR
heterodimer (i.e., to determine which linker attachment produced better binding).
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Figure 9. Comparison of the abilities of 18 and 19 to target MOR and CCR5.

By using calcium mobilization assays to determine the functionality of each bivalent compound
(18 & 19) to the MOR-CCR5 heterodimer, it was concluded that the modification of the amine to the 3position produced a less potent bivalent compound. Whereas both 18 and 19 retained their antagonism
toward MOR (IC50's of 29.9 ± 2.4 and 17.4 ± 5.7, respectively), neither 18 nor 19 produced effective
binding to CCR5 (IC50's of 6240 ± 250 and 14040 ± 350, respectively). Overall, there was a 350-fold
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decrease in activity for 18 but a 700-fold decrease in activity for 19. Moreover, in CCR5 and MOR
radiobinding assays, compound 19 completely lost its affinity to the CCR5 receptor.
After determining the efficacy of the 4-position over the 3-position, further fine-tuning of the
bivalent compound was conducted to increase binding to the CCR5-MOR heterodimer. The 21-atom
spacer in 18 was changed to a 19-atom spacer and a 23-atom spacer in 20 and 21, respectively (Figure
10). This was done because the in silico research conducted by Daniels et al. was inconclusive
regarding the spacer's length.107
Controls to demonstrate MOR-binding (22 and 23) and CCR5-binding (24 and 25) were also
synthesized (Figure 10). Dr. Yunyun Yuan synthesized the bivalent compounds and CCR5-binding
controls (20, 21, 24, 25), whereas Thomas Raborg synthesized the MOR-binding controls (22 and 23).
In this way we set out to test the relative potency of each novel bivalent compound to the original
bivalent compound containing the 21-atom spacer (18).
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Figure 10. Compounds synthesized to target CCR5, MOR and the CCR5-MOR heterodimer.

2.2 6β-Naltrexamine Synthesis
In order to hook up the monoprotected 5- and 9-carbon linkers with naltrexamine through an
amide coupling reaction, the opioid naltrexone, a potent µ-opioid receptor antagonist, would have to be
converted to 6β-naltrexamine (38). 38 was already synthesized according to the synthetic route
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illustrated in scheme 2 by the Portoghese group.124 This two-step synthetic route first converted
naltrexone to a 6β-naltrexamine derivative containing two benzyl groups attached to a tertiary amine,
replacing the keto group at the six position.124 Then, this dibenzylamine derivative was reduced using
Pd/C hydrogenation to form 6β-naltrexamine.124

N
OH

HO

O

N

1) PhCOOH, EtOH, .5h
2) PhCOOH, TsOH, NHBn2
toluene, reflux

OH

3) EtOH, NaCNBH3, MS
HO

O

O

37

36

NBn2

N
OH

10% Pd/C, H2
MeOH, HCl
HO

O

NH2

38
Scheme 1. 6β-naltrexamine (38) synthesis.

The first time the reductive amination reaction was attempted, 1.00 g naltrexone (36) was added
to 75 mL absolute EtOH and 175 mL anhydrous toluene, making a very dilute solution. The reaction
was kept under anhydrous conditions and placed under a Dean-Stark trap, whereby any water formed
from the reaction would be extracted from it (the solvent collected in the Dean-Stark trap was
discarded). Additionally, molecular sieves were added to further prevent the presence of water from
interfering with the second step of the reaction. After the dibenzylamine was added, the reaction was
allowed to reflux for one night.
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In the morning, the solvent mixture was found to have evaporated, leaving a burnt residue at the
bottom of the flask. One hundred and fifty milliliters of toluene was added to the reaction with [1.1]
equivalent NaBH3CN, but, even after two days, 37 did not form (verified by TLC, 9:1:0.01, DCM:
MeOH:NH4OH). The reaction would have to be re-attempted, as the dibenzylamine derivative would
not form.
The second time the reductive amination reaction was attempted, 0.50 g naltrexone was added
to 75 ml absolute EtOH and 175 mL anhydrous toluene, making a more dilute solution than the
previous attempt. The reaction was still kept under anhydrous conditions and placed under a DeanStark trap. [1.2] equivalent dibenzylamine was also added However, this time, 150 mL toluene and 50
mL EtOH were added at the end of the day to ensure that the solvent mixture did not fully evaporate.
In the morning, [1.1] equivalent NaBH3CN was added to the reaction mixture. After two days
the product was confirmed to have formed by TLC (9:1:0.01, DCM: MeOH:NH4OH). The crude
product was filtered and concentrated in a flask, and then the product (37) was recrystallized by 9:1
MeOH:H2O. The reaction yielded 0.250 g product at 34% yield. This is approximately twice as less as
the yield reported by the Portoghese group.124 It was speculated that this was because of the small
amount of starting material (37) used in the reaction (by contrast, the Portoghese group used about 2.00
g naltrexone).
The 6β-naltrexamine intermediate 37 was then subjected to deprotection using Pd/C
hydrogenation. 0.250 g 37 was put in a H2 flask with 10% Pd/C and HCl and placed under H2 gas at 60
psi. 10% Pd/C was added two more times over the course of three days, as the product (38) was having
trouble forming. For example, after the third 10% equivalent was added, TLC (9:1:0.01,
DCM:MeOH:NH4OH) revealed three separate spots, the starting material (37), an intermediate and the
product (38). The reaction mixture was filtered a day after the third 10% Pd/C addition and
recrystallization (9:1, diethyl ether:MeOH) was attempted, but no crystals formed. The precipitate was
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a crude, orange, sticky product with multiple spots on the TLC. It was determined that the reductive
amination reaction would have to be reattempted, this time ensuring that the product (37) was pure
enough so that crystals of 38 would form at the end of the second reaction.
A third reductive amination reaction was attempted, this time with 0.50 g naltrexone (36) added
to 75 mL absolute EtOH and 150 mL toluene. The reaction was again placed under a Dean-Stark trap
with molecular sieves, and [1.2] equivalent dibenzylamine was added. Like in the second attempt, 150
mL toluene and 50 mL EtOH were added to the reaction mixture at the end of the day to ensure that the
solvent would not totally evaporate. On the second day, [1.1] equivalent NaBH3CN was added to the
reaction. When the product (37) formed, the reaction was filtered and concentrated to dryness. The
crude product was again recrystallized in 9:1 MeOH:H2O. No product was left behind in the mother
liquor, so the solid precipitate was dissolved in DCM and further purified using column
chromatography (20:1:0.01, DCM:MeOH:NH4OH) to give 0.260 g 37 at a yield of 35%. This is
approximately twice as less as that reported by the Portoghese group.124 Reasons for this might include
both the amount of SM that was used in the reaction and the dual purification process (i.e., by
recrystallization and purification of the crude recrystallized product).
0.260 g 37 was then placed in a H2 flask with 10% Pd/C and HCl under H2 gas at 60 psi. 10%
Pd/C was added two more times within a period of four days to ensure that the reaction would go to
completion. The reaction was monitored by TLC (9:1:0.01, DCM:MeOH:NH4OH) until completion,
and then it was filtered through celite and concentrated to dryness. The resultant crude produce was
recrystallized in 9:1 diethyl ether:MeOH. However, unlike the first time recrystallization using this
ratio was attempted, the product that precipitated out of the solvent was white and powdery. 0.199 g 38
was extracted at a yield of 96%.

2.3 Synthesis of the monovalent µ-Opioid control compounds
31

2.3.1 Monoprotection of diamines
The monovalent µ-opioid control compound was previously synthesized using the synthetic
route illustrated in scheme 1.120 However, unlike the previous synthesis, which used 1,7diaminoheptane as the starting material, the number of carbon atoms in the diamine were changed from
seven to five and nine (i.e., 1,5-diaminopentane (26) and 1,9-diaminononane (27), respectively) for the
current experiment. The compounds were synthesized in tandem using similar reaction conditions and
reagents.

H2N
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NH2

26, n = 3
27, n = 7

Cbz-Cl
DCM/MeOH
0 - 5 oC

H2N

( )n

NHCbz

28, n = 3
29, n = 7

Scheme 2. Monoprotection of diamines.

First, diaminopentane (26) and diaminononane (27) were monoprotected using a carboxybenzyl
group according to various reported methods.120, 122, 123 The first time this reaction was tried, 1 g of
starting material was added to 300 mL DCM and 300 mL MeOH, making a very dilute solution. The
solution was further diluted by adding [1] equivalent benzyl chloroformate that was dissolved in 200
mL MeOH dropwise over the course of one week at room temperature. After the reaction was
completed, TLC (9:1:0.01 DCM, MeOH, NH4OH) was taken to reveal that the majority spot (UV and
iodine active) was that of the starting material. Some diprotected product formed, but very little
monoprotected product formed. The difficulties of the reaction were further compounded by the fact
that there were numerous byproducts in the reaction mixture that made purification difficult. Yields
from this reaction under these conditions and parameters were 5-8%.
The work-up and purification of the monoprotected product is worthy of note, as many steps
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were taken to ensure that the product was pure enough to initiate the next step in the reaction scheme.
Special emphasis was put on purifying the product in this reaction because, as the first step in the
synthetic route, an impure product would make all following reactions more difficult to initiate and
purify. The difficulties of working with impure starting material were noted even as early as the second
reaction (i.e., the one utilizing diglycolic anhydride in scheme 1), as, the first time it was tried, it was
impossible to recrystallize the product given the impurities mixed with the starting material.
When the crude product had been concentrated to dryness, it was dissolved in DCM and put in a
separation funnel. Then, H2O – which is immiscible with DCM – was put in the separation funnel and
its pH was reduced to 1 using 38% HCl. The purpose of making the water acidic was to ionize the
unprotected diamine and monoprotected diamine and thus make them much more polar than the
diprotected byproduct. It was theorized that, because the diprotected byproduct contained no primary
amines, it would be much harder to ionize than either the unprotected diamine or the monoprotected
diamine, and thus it would remain in the denser, non-polar DCM layer while the other two compounds
became more miscible in water. Once the DCM layer was drained from the separation funnel, the
remaining water layer had its pH increased to 12 ~ 14. This was done in order to make the
monoprotected product less soluble in water and more soluble in DCM. In this way the monoprotected
product was separated from the more polar starting material. Results of the chemical separation were
confirmed with TLC (9:1:0.01 DCM:MeOH:NH4OH).
Once the DCM containing the monoprotected compound was concentrated, it was redissolved
in 1 mL DCM in preparation for column chromatography. Although the monoprotected product had
been separated from its diprotected byproduct and unprotected starting material, there were still other
impurities and byproducts that had formed in the reaction. Many of these had similar Rf values with
the monoprotected product on TLC. The column was done in gradients, starting from 50:1:0.01
DCM:MeOH:NH4OH and becoming progressively more polar. The 1,5-monoprotected diamine was
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quite difficult to purify, as it didn't begin to elute from the column until the ratio was reduced to 5:1
DCM:MeOH. The 1,9-monoprotected diamine was easier to purify, as it was larger and less polar and
therefore eluted from the column at the much higher ration of 10:1 DCM:MeOH. Regardless, both
compounds required another round of column chromatography to separate the monoprotected product
from other byproducts, as there were still impurities with the product in both cases.
The next time the reaction was tried, similar previously reported methods were utilized, but this
time the amount of benzyl chloroformate was modified. Instead of adding [1] equivalent of benzyl
chloroformate, [1.5] equivalent was added in the hope that it would drive the reaction to completion,
thus forming more monoprotected product. This was done due to the large amount of starting material
that remained unreacted the first time the reaction was tried. It was hypothesized that adding more
equivalents of benzyl chloroformate would reduce the amount of starting material in favor of more
monoprotected product. Even though doing so would increase the amount of diprotected byproducts as
well, since there was far more starting material left over after the reaction the first time it was tried, this
result was considered negligible. One gram of the starting material was diluted in 300 mL DCM and
300 mL MeOH, making a very dilute solution, and the [1.5] equivalent benzyl chloroformate was
added with 200 mL MeOH dropwise over the course of one week. After the reaction was completed,
TLC (9:1:0.01 DCM, MeOH, NH4OH) was taken to reveal two dark spots (UV and iodine active) –
assumed to be the monoprotected product and diprotected byproduct – above the spot containing the
starting material. As in the previous reaction, however, many byproducts were revealed to be around
the monoprotected product. This made purification difficult, and the yields from this reaction under
these conditions were also very low (approximately 10-15%).
From both of the previous methods, the first using [1] equivalent benzyl chloroformate and the
latter using [1.5] equivalent benzyl chloroformate, two problems still persisted with the reaction: (1) the
low yield of monoprotected product and (2) the formation of numerous byproducts which made
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purification difficult. The methods previously detailing the reaction, however, suggested modifying the
temperature under which the reaction proceeded in order to decrease the amount of byproducts formed
and increase total product yield.122, 123 According to the literature, decreasing the temperature of the
reaction from room temperature to 5 – 10 oC would result in less diprotected byproduct and less
byproducts similar in size and polarity to the monovalent product, thus making purification much less
difficult and time-consuming.122, 123
The next time the reaction was proceeded by adding 1 g of starting material diluted in 300 mL
DCM and 300 mL MeOH. However, instead of leaving the reaction at room temperature, the
temperature was lowered to 0 – 10 oC and maintained over the course of one week as [1.5] equivalent
benzyl chloroformate was added dropwise. After the reaction was completed, TLC (9:1:0.01 DCM,
MeOH, NH4OH) revealed some starting material left (UV and iodine active), but mostly diprotected
byproduct and monoprotected product. It is interesting to note, however, that some of the byproducts
which had previously appeared on the TLC plate were absent. Because of the absence of these
byproducts, purification was easier, but it was still quite low, at approximately 10 – 20% yield for both
monoprotected products (28 & 29).
Despite the minor improvements in yield from the first reaction, there were still drawbacks to
the reaction that persisted. It seemed that regardless of the amount of benzyl chloroformate used and
regardless of the temperature, there were still going to be numerous byproducts formed, and the
diprotected byproduct would always predominate over the monovalent product. Furthermore, the yield
was still quite low, and it seemed like the reaction would have to be repeated numerous times in order
to gather enough product to go onto the next step in the synthetic scheme. In order to improve the yield
of the reaction and limit the amount of byproducts formed, it was suggested that the reaction be placed
above a Dewar flask containing acetone and dry ice, cooling the temperature to -10 – 0 oC, thus making
the reaction conditions even cooler than attempted previously. Furthermore, using dry ice in acetone
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would make the reduced temperature easier to maintain. It was also suggested that the equivalent of
benzyl chloroformate be modified to [.5] equivalent in order to reduce the chances of byproduct
formation, in particular the diprotected byproduct. Furthermore, because of the cooler temperatures
and smaller equivalent of benzyl chloroformate, less solvent would be needed to conduct the reaction.
In conclusion, two conditions would be changed for the next reaction: the temperature and equivalent
of benzyl chloroformate. These modified parameters would decrease the amount of solvent required
for the reaction to work.
As before, 1 g of the starting material was placed in a flask. This time, however, only 250 mL
DCM was used as a solvent. The reaction temperature was reduced to -10 – 0 oC using acetone and dry
ice, and [.5] equivalent benzyl chloroformate in 50 mL DCM was added dropwise over the course of
one day. The temperature was monitored and dry ice and acetone were continuously added in order to
maintain a constant low temperature. After the reaction was complete, TLC (9:1:0.01 DCM, MeOH,
NH4OH) revealed little-to-no starting material, no diprotected byproduct and very little additional
byproducts around the monoprotected product (UV and iodine active). The largest spot was the
monoprotected product. The reaction was concentrated and purified using column chromatography
(5:1:0.01 DCM, MeOH, NH4OH for the monoprotected diaminopentane and 9:1:0.01 DCM, MeOH,
NH4OH for the monoprotected diaminononane). 0.770 g (28) was collected at a yield of 33%, by far
the greatest for the reaction involving 1,5-diaminopentane starting material. 0.444 g (29) was collected
at a yield of 24%, also the greatest for the reaction involving 1,9-diaminononane starting material. The
compounds were verified by 1H NMR.

2.3.2 Monoprotected Diamines Reacting with Dyglycolic Anhydride
The next step in the reaction scheme consisted of using 28 or 29 as the starting material and
converting it to a carboxylic acid by coupling its unprotected primary amino group with diglycolic
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anhydride. This reaction required an exact measurement of the amount of starting material, as reacting
it with any more or less than [1] equivalent diglycolic anhydride resulted in a reaction mixture that was
difficult to purify by recrystallization (N.B., the carboxylic acid product could not be separated from
the reaction mixture by column chromatography, given the polarity of the compound). The first time
the reaction was attempted, about 0.100 g of 28 was put inside a flask with 3 mL THF and the reaction
temperature was reduced to 0 – 5 oC using an ice-water bath. Then, [1] equivalent diglycolic anhydride
was added and the ice-water bath was removed, thus allowing the reaction to reach room temperature.
After one day, the reaction was concentrated and recrystallization in diethyl ether:MeOH (9:0.01) was
attempted. The solvent ratios were varied, but the product did not form. Given that the reported yield
for this reaction was over 90%, it was assumed that the starting material was not weighed accurately,
and this was why the product did not recrystallize out of the solution.
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Scheme 3. Cbz-protected diamines reacting with diglycolic anhydride.

The second time the reaction was tried, the starting material was dried using a vacuum pump in
a small 100 mL flask in order to increase the accuracy of the measured weight. After this, the starting
material was put in a flask with THF and the temperature was again reduced to 0 – 5 oC using an icewater bath. [1] equivalent diglycolic anhydride was added and the ice-water bath was removed,
allowing the reaction to reach room temperature. A day later, the reaction was concentrated and
recrystallization was attempted using diethyl ether:MeOH (9:0.01). This time the product was able to
recrystallize out of the reaction mixture after one day of stirring in the diethyl ether:MeOH solvent
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mixture. About 0.270 g 30 was obtained at a yield of 30% and 0.170 g 31 was obtained at a yield of
also 30%. While adequate for conducting the remaining reactions in the synthetic scheme, these yields
were much lower than yield reported in the literature.120

2.3.3 Monoprotected Intermediates Undergo Amide-Coupling Reaction with 6β-naltrexamine
Compounds 30 and 31 were then attached to 6β-naltrexamine (see scheme 2 for synthetic route
of 6β-naltrexamine) via an amide coupling reaction. The reaction consisted of putting the acid linker
(30 or 31) in 1 mL anhydrous DMF, forming a concentrated 1 M solution. This solution was allowed to
stir overnight with molecular sieves under N2 gas protection in order to ensure anhydrous conditions.
This stage of the reaction was critical, as water would impede the formation of the acid-EDCI
intermediate, which was required for the coupling reaction to occur in a timely manner. The following
day, [1.5] equivalent HOBt and [1.5] equivalent EDCI catalysts were added to the reaction according to
reported methods.120 Then, [1] equivalent 6β-naltrexamine in 1 mL anhydrous DMF was added
dropwise for the coupling reaction to proceed. The reaction was given a few days to go to completion
and TLC (9:1:0.01 DCM:MeOH:NH4OH) was taken to ensure that the 6β-naltrexamine starting
material was consumed. For the formation of the 6β-naltrexamine with the 1,9-monoprotected acid
control, an additional [.5] equivalent of EDCI was added to the reaction in order for the starting
material to be consumed. Once the starting material was consumed, the reaction was filtered through
celite and concentrated to dryness. The crude product was recrystallized in 20:1:0.01
DCM:MeOH:NH4OH column chromatography. 0.165 g 32 was obtained at a yield of 60%, and 0.170
g 33 was obtained at a yield of 43%. These results mimic the yield reported in the literature.120
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Scheme 4. Amide-coupling reaction involving the protected diamine and 6β-naltrexamine.

2.3.4 Deprotection
Compounds 32 and 33 were then subjected to deprotection. For this reaction, the starting
material was placed inside a H2 flask with MeOH and 10% Pd/C. The reaction took about three days
for both starting materials. Over the course of the reaction time, multiple 10% Pd/C equivalents were
added to the reaction in order to drive it to completion (N.B., the reaction was monitored by 6:1:0.01
DCM:MeOH:NH4OH). The crude product was filtered through celite and concentrated to dryness.
0.086 g 34 was obtained at a yield of 67%, which was somewhat lower that the yield reported in the
literature.1 0.091 g 35 was obtained at a yield of 72%, which was also lower than previously reported
yields.1 It is noteworthy that both compounds were quite unstable owing to the primary amine that
resulted from the deprotection reaction. In fact, the first time the reaction was attempted with 32, the
product (34) degraded from a rise in room temperature that took place when the laboratory's airconditioning unit was switched off. Therefore, the second time the reaction was completed, the product
was placed inside the freezer until the next step in the reaction scheme was attempted.
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2.3.5 Final Product Synthesis
For the final step in the reaction scheme, compounds 34 and 35 were reacted with an acidic
“cap” through an amide coupling mechanism in order to ensure their stability when performing assays
at room temperature (see scheme 1 for the cap's structure). First, the cap was placed in 1 mL DMF
with molecular sieves and under N2 protection to ensure anhydrous conditions. Like in the previous
amide coupling reaction, the presence of H2O would disrupt the formation of the acid-EDCI complex
necessary for the reaction to proceed in a timely manner. After one day, [1.5] equivalent HOBt and
[1.5] equivalent EDCI were added to the reaction at 0 oC and the reaction was allowed to warm up to
room temperature. Then, 34 or 35 was mixed with 1 mL DMF and added dropwise to the reaction.
After three days, the reaction was monitored by TLC (7:1:0.01 DCM:MeOH:NH4OH) to reveal that the
amine starting material was no longer present in the reaction mixture. There was a main product spot
(UV and iodine active) present with lots of byproducts and remaining catalyst. The reaction was
filtered, concentrated to dryness and purified by column chromatography (10:1:0.01
DCM:MeOH:NH4OH) The reaction yield was quite low for both products, but this result had already
been reported in the literature.1 0.030 g 22 was synthesized at a yield of 30%, and 0.030 g 23 was
synthesized at a yield of 25%.
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Both products were coverted to hydrochloride salts and recrystallized in 9:0.1 diethyl
ether:MeOH.

3. In Vitro Studies
3.1 Results from Calcium Mobilization Assays with Initial 21-Atom Bivalent Compound
In total, approximately 9 compounds were synthesized for the study of the CCR5-MOR
heterodimer (N.B., this does not include the 3-position spacer and its maraviroc control, which were
found to be less efficacious at binding to CCR5 and the CCR5-MOR heterodimer relative to the 4position spacer and its control). Figure 11 shows the first 3 of these compounds, the 21-atom spacer
and its two monovalent controls, which were synthesized by Dr. Yunyun Yuan. These compounds were
tested in either CCR5- or MOR- cells and cells expressing both CCR5 and MOR.
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Figure 11. Original 21-atom bivalent compound (18) with maraviroc and 6β-naltrexamine controls.

Calcium mobilization assays were chosen to test the functional activity of the compounds due to
their simplicity.125 In these assays, GPCR signaling causes the release of intracellular calcium stores.125
Ideally, the IC50's of these compounds should match both maraviroc and naltrexone, as this would
indicate good inhibition at the CCR5 and MOR receptors. Figure 12 shows a schematic representation
of the mechanism behind the calcium mobilization assay.
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Figure 12. Schematic representation of a calcium mobilization assay.

The results for compound 18 in assays containing CCR5, MOR or the CCR5-MOR heterodimer
are as follows. In assays utilizing human acute lymphoblastic leukemia (MOLT-4) cells transfected
with CCR5, 18 had an IC50 of 130 ± 28 nM, an approximately 60 fold-decrease in activity relative to
maraviroc, which had an IC50 of 2.2 ± 0.31 nM.120 While this fold-decrease in activity is significant, it
is expected given the attachment of maraviroc to a spacer and another molecule. However, the
maraviroc control containing just a spacer had a much larger decrease in activity relative to maraviroc,
with an IC50 of 620 ± 36 nM (i.e., a 600 fold-decrease in activity).120 More maraviroc controls and
spacer molecules would have to be synthesized and tested in order to see whether or not this significant
fold-decrease was consistent with attaching a spacer to the 4-position of maraviroc.
In chinese hamster ovarian (CHO) cells containing hMOR, 18 only had a slight fold-decrease in
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activity relative to naltrexone. 18's IC50 was 40 ± 4.8 nM, whereas naltrexone had an IC50 of 8.9 ± 0.87
nM (a fold-decrease of 4.5).120 The 6β-naltrexamine spacer had an IC50 of 17 ± 4.9 nM, or a folddecrease of 1.9, confirming that a spacer attached to the 6 position was tolerable.120
Finally, in an assay containing CHO cells transfected with both CCR5 and MOR genes, 18 was
found to have an IC50 of 17 ± 5.7 nM at the hMOR receptor, only a 3 fold-decrease from naltrexone.120
This further confirms the tolerability of a spacer attached to the 6-position of naltrexone. However, at
the CCR5 receptor, the compound was found to have an IC50 of 6200 ± 250, a 350 fold-decrease
relative to maraviroc.120 Thus, more compounds with modifications at the 4-position of maraviroc
would have to be tested in order to verify its viability or lack thereof.
Figure 13 contains the other six compounds synthesized and tested in calcium mobilization
assays. These compounds include both 19- and 23-atom bivalent compounds (20 & 21) along with
their 6β-naltrexamine (22 & 23) and maraviroc (24 & 25) controls. Dr. Yunyun Yuan synthesized 20,
21, 24 and 25. Thomas Raborg synthesized 22 and 23. The maraviroc containing compounds were
tested using MOLT-4 cells transfected with CCR5, whereas the 6β-naltrexamine compounds were
tested using CHO cells transfected with hMOR.
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Figure 13. Two bivalent compounds of varying spacer length and their controls.

3.2 MOR-Radiobinding Assay
Before calcium mobilization assays were performed on the compounds in Figure 13, a binding
assay was run in order to verify that the 6β-naltrexamine-containing compounds could bind to the
MOR receptor at high affinity. This assay was run by Dr. Yunyun Yuan using compounds synthesized
by both Dr. Yuan and Thomas Raborg. Table 5 shows the results of the MOR-radiobinding assay for
the 6β-naltrexamine-containing compounds. As one can observe, the bivalents (20 & 21) and their 6βnaltrexamine controls (22 & 23) did not have significant fold-decreases in affinity relative to
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naltrexone. This indicates that all the compounds were relatively potent for the MOR receptor.

Compound

Table 5. MOR-radiobinding assay
MOR Ki (nM)

Naltrexone

0.7 ± 0.1

-

20

3.8 ± 0.55

5.4

22

0.78 ± 0.12

1.1

21

1.1 ± 0.08

1.6

23

6.5 ± 0.16

9.3

Fold-decrease in Affinity
Compared to Naltrexone

A CCR5-radiobinding assay also needs to be conducted in the future to test the relative
potencies of each of the maraviroc-containing compounds. This might help verify the calcium
mobilization assay's result that attachments to the phenyl ring of maraviroc are not tolerated for CCR5
binding.

3.3 CCR5-MOLT4 Calcium Mobilization Assay
First the bivalent compounds and their maraviroc controls were tested for CCR5 agonism and
antagonism in assays utilizing MOLT-4 cells transfected with CCR5. In assays testing for agonism,
there was no apparent agonism of CCR5 for any of the molecules. Prior to testing for antagonism, the
MOLT-4 cells were transfected with a chimeric G protein, Gqi5, in order to stimulate calcium signaling.
A range of concentrations was set up similar to the range of concentrations that gave accurate IC50's of
the original 21-atom bivalent spacer and its maraviroc control. Each assay well also contained a
specific concentration of RANTES, a CCR5 agonist, in order to test the inhibition of calcium
mobilization. All compound concentrations were run in triplicate and tested three separate times.
Like for the 21-atom bivalent molecule (18) and its maraviroc control, the 19- and 21-atom
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bivalents (20 & 21) and their maraviroc controls (24 & 25) also demonstrated decreased antagonism
relative to maraviroc for CCR5 (Table 5). Thus, it appears as if modifications to the phenyl ring of
maraviroc are not well tolerated for CCR5-binding. Therefore, future synthetic alterations to the
bivalent compound may involve changing the spacer's point-of-attachment to maraviroc.

Table 6. Antagonism of calcium mobilization in RANTES-stimulated MOLT-4 cells
Compound
CCR5 Antagonism IC50 (nM)
Fold-decrease in Activity
Compared to Maraviroc
Maraviroc

2.2 ± 0.3

-

20

2400 ± 620

1100

24

950 ± 34

430

21

540 ± 79

250

25

390 ± 51

180

A recent paper published the crystal structure of maraviroc bound to CCR5. It was found that,
contrary to a previously reported modeling study,121 the phenyl ring of maraviroc faces inward at the
maraviroc binding pocket and has many favorable hydrophobic interactions with certain amino acid R
groups.126 This fact demonstrates the implausibility of attaching the spacer to the phenyl ring of
maraviroc, as doing so would significantly change its traditional inhibitory binding mode. While this
puts a damper on the research project this laboratory has been conducting, the purported binding mode
of maraviroc introduces new locations to which a future spacer may be attached.
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Figure 14. Crystal structure of maraviroc bound to CCR5.126

3.4 hMOR-CHO Calcium Mobilization Assay
MOR agonism and antagonism were also tested using calcium mobilization assays. However,
this time the targeted protein (i.e., hMOR) was transfected in CHO cells instead of MOLT-4 cells.
Again, like in the MOLT-4 calcium assays, Gqi5 was transfected into the CHO cells to stimulate
calcium mobilization upon agonist binding.125 The compounds demonstrated no agonism. Using the
MOR agonist DAMGO, the compounds were tested for their ability to inhibit calcium mobilization,
and the results were tabulated in Table 6.
According to Table 6, the bivalent compounds (20 & 21) and their monovalent 6β-naltrexamine
controls (22 & 23) did not contain significant fold-decreases in activity relative to the traditional MOR
antagonist naltrexone. The compound with the greatest decrease in activity, 22, only had a 32 folddecrease in activity relative to naltrexone. This corresponds to a fold-decrease of only two orders of
magnitude. This demonstrates that the 6-position of the naltrexone molecule can tolerate numerous
structural modifications and still be able to bind to MOR. Future modifications on the bivalent
compound can probably maintain the spacer at the 6-position of 6β-naltrexamine without worry of a
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substantial decrease in activity for MOR.

Table 7. Antagonism of calcium mobilization in DAMGO-stimulated hMOR-CHO cells.
Compound
MOR Antagonism IC50 (nM)
Fold-decrease in Activity
Compared to Maraviroc
Naltrexone

2.9 ± 0.27

-

20

22 ± 5.6

7.6

22

92 ± 020

32

21

22 ± 3.7

7.6

23

41 ± 25

14

3.5 Conclusions from In Vitro Studies
Regardless of the decrease in activity for the CCR5 receptor, the bivalent compounds still need
to be tested in calcium mobilization assays involving a cell line transfected with both CCR5 and MOR.
While modifications to the phenyl ring of maraviroc are not tolerated for binding to CCR5, and
therefore a new spacer molecule needs to be synthesized in order to produce better binding, testing
these two new bivalent compounds in a cell-line containing both receptors may indicate which spacer
length is optimal for simultaneous CCR5-MOR binding. If either the 19-atom bivalent (20) or the 23atom bivalent (23) is significantly better than the 21-atom bivalent (18) at inhibiting calcium
mobilization in cells containing both receptors, then future modifications to the spacer's point-ofattachment to maraviroc may incorporate this change in spacer length.

4. In Silico Studies
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4.1 Introduction to Conformational Analysis
A molecule can undergo spatial rearrangements that do not alter its basic chemical structure.
The study of the differences between these rearrangements – called conformations – is called
conformational analysis.126–128 These spatial rearrangements occur through changes in rotation around a
single chemical bond that do not affect the bond's length or physical characteristics. If a particular
rotation around a single chemical bond produces interactions that are not favorable within a molecule,
then the resultant conformation is not considered viable.126 The corollary to this is that if a rotation
around a chemical bond does produce favorable interactions within a molecule, then the resultant
conformation is deemed viable. Since a receptor often interacts with a ligand only when that ligand is
in a specific conformation, and since the number of viable conformations a molecule can undergo is
limited, it is important to identify possible binding conformations. Furthermore, since a molecule's
external environment is subject to change (and it can undergo drastic changes), it is important to
identify all viable conformations of a molecule independent of its external environment.126
Using conformational analysis molecular modeling software, there are two important ways to
identify viable conformations of a molecule.126 One way is through energy minimization, i.e., through
rearranging the atoms of a molecule until it adopts a global minimum energy conformation.126 This
method is based on the assumption that a molecule will adopt a conformation either identical or similar
to its lowest energy state in reality. When this method is adopted, a molecule will rearrange in a
manner to produce the least torsional strain between atoms around a single chemical bond and also try
to maximize intramolecular van Der Waals interactions.126 When this procedure is conducted, the
product is a single molecule. Given that this method may produce a conformation that is not viable for
binding to a receptor, another method, termed systematic conformational search analysis, is sometimes
required.126 Using this method, a set of rotatable bonds in a molecule is identified and those rotatable
bonds are altered with respect to all other bonds in a molecule.126 In other words, each rotatable bond is
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altered and examined as a function to all other molecular bonds. For each different conformation that
is achieved as a result of a single chemical bond rotation, all internal distances are computed, and a
conformation is rejected if the distance between the interacting species is greater than the sum of the
van der Waals radii.126 By using this method, all viable conformers within a certain energy range of the
global minimum are identified. Unlike the global minimization analysis, the systematic conformational
search analysis method produces a set of viable conformers that can exist in solution. This method is
useful in that it produces multiple viable conformations that can exist besides the global minimum.

4.2 Choosing a Conformational Analysis Software
Multiple molecular modeling programs exist for performing conformational analysis. Among
them are Systematic Conformational Search, Grid Search, Random Conformation Search, GA
Conformational Search and Confort Conformational Analysis Modeling Software.126, 127 Methods such
as Systematic Conformational Search, Grid Search, Random Conformation Search and GA
Conformational Search rotate an individual chemical bond within a specified increment until a
minimum energy is achieved.126, 127 Although these methods produce a set of viable conformations, they
are not exhaustive and they are poor at calculating global minima. Confort, on the other hand, has
algorithms both for calculating global minima and producing a set of viable, diverse conformations that
approximate a global minimum.126 Confort, therefore, was used in the following conformational
analysis study rather than other methods.
There were two purposes regarding the conformational analysis study on the 19-, 21- and 23atom spacers: 1) to see if all three spacer had viable binding conformations (i.e., viable in the sense that
the molecules could potentially bind to two different GPCR's simultaneously), and 2) to see if all three
spacers adopted similar viable conformations. Completion of the former objective could be used to
hypothesize that the molecules actually bind to their target receptors simultaneously. Completion of the
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latter objective could be used to hypothesize that the 3 spacers can adopt identical binding
conformations in solution and, therefore, any difference in binding between the three molecules is
primarily because of spacer length (and not differences in conformation).

4.3 Molecular Building
All ligands used in the conformational analysis studies were built with standard bonds and
angles using the molecular modeling software SYBYL-X 2.0. The proper stereochemical arrangements
were also assigned for each asymmetric carbon to ensure viability of results and uniform spatial
arrangements between each spacer molecule. For the process of energy minimization (to establish a
local minimum conformation for each small molecule), each small molecule was assigned GasteigerHuckel charges and then minimized using the Tripos Force Field.

4.4 Global Minimization Conformational Analysis
In order to identify viable conformations for the three spacer molecules, global minimization
was conducted using Confort. Again, this technique assumes that a molecule will adopt a conformation
similar to its global minimum in actuality.128 However, before running the global minimum simulation,
certain parameters were set in order to achieve optimal results. First, the search was set to include
analyses of all rotatable bonds and a maximum number of concurrently searched rotors. Maximums of
100 acyclic bonds, 20 ring system bonds and 10 single-ring bonds were defined. Then, the precision of
the results was set to .001 kcal/mol and Gasteiger-Huckel charges were applied. The output file was set
to include the the global minimum with 9 lowest-energy conformers approximating the global
minimum. After these parameters were set, the program was run for each spacer individually.
For the 19-, 21- and 23-atom spacers, each molecule adopted a “folded” conformation, one in
which the spacer contorted to bring the maraviroc portion of the molecule in close proximity with the
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6β-naltrexamine portion (see Figures 14, 15, and 16). This makes sense because in order to achieve a
global minimum a molecule has to contort in such a way as to allow maximum van der Waals
interactions. Thus, the molecules contorted at the center of the spacer, as this allowed the molecules'
two groups (i.e., maraviroc and 6β-naltrexamine) to best engage in van der Waals interactions. While
this conformational change was similar in all three spacer molecules (thus producing similar global
minimum conformations), it should be noted that this change did not produce a molecule conducive for
binding to two different receptors. If the maraviroc portion interacts with the naltrexamine portion in a
manner similar to that seen in the three figures, then how is the molecule going to bind to two different
receptors at once? Furthermore, such a conformation would negate the importance of spacer length in
binding to the two receptors. From this study, it was obvious that a set of diverse conformers for each
of the three molecules was necessary to verify that the molecules adopted plausible binding
conformations.

Figure 15. Global minimum of the 19-atom spacer.
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Figure 16. Global minimum of the 21-atom spacer.
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Figure 17. Global minimum of the 23-atom spacer.

4.5 DIVERSESET Conformational Analysis
DIVERSESET, a Confort algorithm used to generate sets of different and diverse
conformations, was implemented in order to obtain plausible and viable conformations for each
molecule. When using DIVERSESET, it is still assumed that the the global minimum is the most likely
conformation to exist in reality. However, DIVERSESET also produces many low-energy
conformations that approximate the global minimum and are therefore also likely to exist in solution.
Like in the global minimization analysis, the search options were also set to include all rotatable bonds
and a maximum number of concurrently searched rotors. The precision was set to .001 kcal/mol and
each molecule was assigned Gasteiger-Huckel electrostatics. This time, however, the software was set
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to generate a set of molecules (500 max.). The output was further optimized by including a maximum
output number of 500 diverse molecular conformations within 100 kcal/mol of the minimum. The
program was then run for all three spacer molecules individually (the Figures 17, 18, and 19 for
results).
Unlike in the global minimization analysis, the DIVERSESET algorithm produced
conformations for each spacer that allowed it to adopt an “elongated” spatial arrangement. That is to
say, many of the low-energy conformers could theoretically bind to both the hMOR receptor and CCR5
receptor at once, unlike the 3 global minima generated from the global minimization analysis. Looking
at Figures 18, 19, and 20, in which 10 low-energy conformers were superimposed upon one another, we
can see similar elongated conformations for all three spacers (elongated in the sense that the maraviroc
and naltrexamine portions are kept separate from one another). Because of the similar conformations
shared by the three spacer molecules, it can be hypothesized that any differences in binding activity are
attributable to the length of the spacer and not drastic differences in conformation. Therefore, the
DIVERSESET algorithm has produced results consistent with the two purposes of the conformational
analysis study, i.e., to verify conformational similarity between the three spacers and to verify their
viability in binding to two different receptors at once.
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Figure 18. Diverse set conformational ensemble of the 19-atom spacer.
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Figure 19. Diverse set conformational ensemble of the 21-atom spacer consisting.
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Figure 20. Diverse set conformational ensemble of the 23-atom spacer
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5. Experimental
5.1 Chemistry Intermediates

N
OH

HO

O

N

37
(4R, 4aS, 7R, 7aR, 12bS)-3-(cyclopropylmethyl)-7-(dibenzylamino)-2,3,4,4a,5,6,7,7a-octahydro-1H4,12-methanobenzofuro[3,2-e]isoquinoline-4a,9-diol (37). Naltrexone, free base, (0.5 g, 0.001460 mol)
was dissolved in 50 mL absolute EtOH. Benzoic acid (1.1 eq, 0.18 g, 0.0001474 mol) was added and
the mixture was allowed to stir for 30 minutes under N2 protection. 150 mL toluene was added to the
flask with benzoic acid (1.1 eq, 0.18 g, 0.001474 mol), dibenzylamine (1.2 eq, 0.34 mL, 0.001812 mol)
and a trace amount of p-toluenesulfonic acid. The reaction was refluxed for 24 hours under N2
protection with a Dean-Stark trap to remove any H2O produced from the reaction. One hundred and
fifty mL of toluene was added during the course of the day. One hundred mL EtOH, molecular sieves,
and NaBH3CN (1.1 eq, 0.100 g, 0.001591 mol) were added and allowed to stir under N2 protection for
24 hours. The mixture was then filtered, rotovaped and re-dissolved in dichloromethane with 3%
aqueous NH4OH. The chloroform was rotovaped and (37) was recrystallized in 9:1 MeOH/H2O to give
0.260 g at 35% yield. 1H NMR (400 MHz, CDCl3) δ 0.096 (m, 2H), 0.495 (m, 2H), 0.815 (m, 1H),
1.230 (td, J = 10.4, 2.8 Hz, 1H), 1.409 (dd, J = 10.3, 2.4 Hz, 1H), 1.575 (m, 1H), 1.681 (m, 1H), 1.9552.119 (m, 2H), 2.170-2.244 (m, 1H), 2.327 (m, 2H), 2.475 (dd, J = 12.6, 5.8 Hz, 1H), 2.547-2.62 (m,
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2H), 2.971 (m, 1H), 3.593 (d, J = 14.2 Hz, 1H), 3.874 (m, 2H), 4.693 (d, J = 7.8 Hz, 1H), 6.420 (d, J =
8 Hz, 1H), 6.551 (d, J = 8 Hz) 7.819 (m, 2H), 7.279 (m, 5H), 4.222 (d, J = 7.2, 4H).

N

HO

OH

O

NH2

38
6β-naltrexamine (38). In a 250 mL hydrogenation flask, 37 (0.260 g, 0.0004990 mol) was dissolved in
5 mL MeOH. 10% Pd/C (0.026 g, 10% w/w) and concentrated HCl (2 eq, 0.06 mL, 0.002036 mol) was
added. The flask was placed on a hydrogenator at 60 psi H2 gas for 24 hours and monitored with TLC
(10:1:0.01 DCM:MeOH:NH4OH). Once completed, the reaction mixture was filtered through celite and
evaporated. 38 was recrystallized in 9:1 diethyl ether:MeOH to give a total of 0.199 g x2
hydrochloride salt, giving a yield of 96%. 1H NMR (400 MHz, DMSO-d6) δ 0.41 (m, 1H), 0.51 (m,
1H), 0.59 (m, 1H), 0.67 (m, 1H), 1.06 (m, 1H), 1.32 (m, 1H), 1.46 (d, J = 8.8 Hz, 1H), 1.78 (m, 1H),
1.82 (d, J = 14.4 Hz, 1H), 1.99 (q, J = 12.5, Hz, 1H), 2.50 (m, 2H), 2.90 (m, 2H), 3.04 (d, J1 = 6.0 Hz,
J2 = 18.8 Hz, 2H), 3.33 (m, 2H), 3.90 (d, J = 4.8 Hz, 1H), 4.68 (d, J = 7.2 Hz, 1H), 6.40 (brs, 1H), 6.67
(d, J = 8.0 Hz, 1H), 6.80 (d, J = 8.0 Hz, 1H), 8.43 (m, 2H, exchangeable), 8.91 (brs, 1H,
exchangeable), 9.58 (s, 1H, exchangeable).

O
H2N

N
H

O

28
(5-Amino-pentyl)-carbamic acid benzyl ester (28). In a 500 mL flask, 1,5-diaminopentane (1 eq, 1 g,
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0.009804 mol) was dissolved in 250 mL DCM and stirred above a Dewar container containing 2-10 dry
ice cubes and acetone. Temperature was set to 0-5 oC. To the reaction mixture, Cbz-Cl (0.5 eq, 0.84 g,
0.004924 mol) in 250 mL DCM was added dropwise for 12 hours while keeping the temperature at 0-5
o

C. After the addition, the reaction mixture was evaporated to dryness and concentrated with a vacuum

pump. The crude product was then purified with column chromatography (5:1:0.01
DCM:MeOH:NH4OH) to give 0.770 g 28 at 33% yield. 1H NMR (400 MHz, CDCl3) δ 1.345 (m, 2H),
1.500 (m, 4H), 2.706 (t, J = 7.06 Hz, 2H), 3.204 (q, J = 6.4 Hz, 2H), 4.816 (s, 1H), 5.094 (s, 2H), 7.525
(m, 5H).

O
H2N

N
H

O

29
(9-Amino-nonyl)-carbamic acid benzyl ester (29). In a 500 mL flask, 1,9-diaminononane (1 eq, 1 g,
0.006300 mol) was dissolved in 250 mL DCM and stirred above a Dewar container containing 2-10 dry
ice cubes and acetone. Temperature was set to 0-5 oC. To the reaction mixture, Cbz-Cl (0.5 eq, 0.49 g,
0.002872 mol) in 250 mL DCM was added dropwise for 12 hours while keeping the temperature at 0-5
o

C. After the addition, the reaction mixture was evaporated to dryness and concentrated with a vacuum

pump. The crude product was then purified with column chromatography (10:1:0.01
DCM:MeOH:NH4OH) to give 0.440 g 29 at 24% yield. 1H NMR (400 MHz, CDCl3) δ 1.286 (broad s,
10H), 1.489 (brs, 4H), 2.731 (t, J = 7.06 Hz, 2H), 3.187 (q, J = 6.4 Hz, 2H), 4.740 (s, 1H), 5.094 (s,
2H), 7.348 (m, 5H).
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30
[(5-Benzyloxycarbonylamino-pentylcarbamoyl)-methoxy]-acetic acid (30). 28 (1 eq, 0.770 g, 0.003257
mol) was dissolved in 18 mL THF above an ice-water bath at 0 oC. Digylcolic anhydride (1 eq, 0.38 g,
0.003276 mol) was added to the mixture, the water bath was removed and the reaction was allowed to
continue at room temperature. The solution was stirred overnight and then evaporated to dryness. The
crude product was recrystallized in 9:1 MeOH:diethyl ether to give 0.270 g at a yield of 30%. 1H NMR
(400 MHz, CDCl3) δ 1.352 (m, 2H), 1.534 (m, 4H), 3.113 (t, J = 6.9 Hz, 2H), 3.239 (t, J = 6.9 Hz, 2H),
4.045 (s, 2H), 4.171 (s, 2H), 5.057 (s, 2H), 7.308 (m, 5H).
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31
[(9-Benzyloxycarbonylamino-nonylcarbamoyl)-methoxy]-acetic acid (31). 29 (1 eq, 0.416 g, 0.001423
mol) was dissolved in 10 mL THF above an ice-water bath at 0 oC. Digylcolic anhydride (1.1 eq, 0.18
g, 0.001442 mol) was added to the mixture, the water bath was removed and the reaction was allowed
to continue at room temperature. The solution was stirred overnight and then evaporated to dryness.
The crude product was recrystallized in 9:1 MeOH:diethyl ether to give 0.170 g at a yield of 30%. 1H
NMR (400 MHz, CDCl3) δ 1.316 (brs, 10H), 1.512 (m, 4H), 3.095 (t, J = 6.9 Hz, 2H), 3.253 (t, J = 6.9
Hz, 2H), 4.046 (s, 2H), 4.180 (s, 2H), 5.058 (s, 2H), 7.308 (m, 5H).
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32

benzyl(5-(2-(2-(((4R, 4aS, 7R, 7aR,12bS)-3-(cyclopropylmethyl)-4a,9-dihydroxy-2,3,4,4a,5,6,7,7aoctahydro-1H-4,12-methanobenzofuro[3,2-e]isoquinolin-7-yl)amino)-2oxoethoxy)acetamido)pentyl)carbamate (32). 30 (1 eq, 0.145 g, 0.0004117 mol) was dissolved with 1
mL DMF in a 5 mL flask. To the solution, 1-hydroxybenzotriazole hydrate (1.5 eq, 0.083 g, 0.0006141
mol), triethylamine (6 eq, 0.166 g, 0.001644 mol) and molecular sieves were added and the reaction
was placed under N2 protection above an ice-water bath at 0 oC. N-(3-dimethylaminopropyl)-N'ethylcarbodiimide hydrochloride (1.5 eq, 0.096 g, 0.0006194 mol) was added and the water bath was
removed, thus allowing the reaction to return to RT. 6β-naltrexamine (40) (1 eq, 0.171 g, 0.0004120
mol) was dissolved in 1 mL DMF and added to the reaction dropwise. The reaction was monitored with
TLC (10:1:0.01 DCM:MeOH:NH4OH) every 24 hours until completion and then filtered and
evaporated to dryness. Column chromatography was conducted on the crude product (20:1:0.01
DCM:MeOH, NH4OH) to obtain 0.165 g of 32 at a yield of 60%. 1H NMR (400 MHz, MeOD) δ .0414
(brs, 2H), 0.752 (d, J = 7.6 Hz, 2H), 1.041 (s, 1H), 1.306 (m, 4H), 1.530 (m, 6H), 1.712 (m, 2H), 1.986
(m, 1H), 2.529 (s, 2H), 2.744 (m, 2H), 2.989 (m, 2H), 3.118 (m, 2H), 3.204 (m, 2H), 3.725 (m, 2H),
4.073 (s, 4H), 4.653 (s, 1H), 5.060 (s, 2H), 6.715 (m, 2H), 7.277 (m, 5H), 7.698 (t, J = 5.5 Hz, 1H).
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33

benzyl(9-(2-(2-(((4R, 4aS, 7R, 7aR,12bS)-3-(cyclopropylmethyl)-4a,9-dihydroxy-2,3,4,4a,5,6,7,7aoctahydro-1H-4,12-methanobenzofuro[3,2-e]isoquinolin-7-yl)amino)-2oxoethoxy)acetamido)nonyl)carbamate (33). 31 (1 eq, 0.220 g, 0.0005392 mol) was dissolved with 1
mL DMF in a 5 mL flask. To the solution, 1-hydroxybenzotriazole hydrate (1.5 eq, 0.109 g, 0.0008074
mol), triethylamine (6 eq, 0.220 g, 0.002178 mol) and molecular sieves were added and the reaction
was placed under N2 protection above an ice-water bath at 0 oC. N-(3-dimethylaminopropyl)-N'ethylcarbodiimide hydrochloride (1.5 eq, 0.126 g, 0.0008129 mol) was added and the water bath was
removed, thus allowing the reaction to return to RT. 6β-naltrexamine (40) (1 eq, 0.224 g, 0.0005398
mol) was dissolved in 1 mL DMF and added to the reaction dropwise. The reaction was monitored with
TLC (10:1:0.01 DCM:MeOH:NH4OH) every 24 hours until completion and then filtered and
evaporated to dryness. Column chromatography was conducted on the crude product (30:1:0.01
DCM:MeOH, NH4OH) to obtain 0.170 g of 33 at a yield of 43%. 1H NMR (400 MHz, MeOD) δ 0.265
(m, 2H), 0.605 (m, 2H), 0.958 (m, 1H), 1.323 (brs, 12H), 1.477 (m, 6H), 1.616 (m, 2H), 1.952 (m, 1H),
2.246 (m, 2H), 2.701 (m, 2H), 3.092 (s, 2H), 3.261 (s, 3H), 3.480 (s, 2H), 3.748 (s, 1H), 4.080 (s, 4H),
4.561 (s, 1H), 5.057 (s, 2H), 6.665 (s, 2H), 7.332 (m, 5H), 7.753 (t, J = 5.5, 1H).
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34

N-(5-aminopentyl)-2-(2-(((4R, 4aS, 7R, 7aR, 12bS)-3-(cyclopropylmethyl)-4a,9-dihyroxy2,3,4,4a,5,6,7,7a-octahydro-1H-4,12-methanobenzofuro[3,2-e]isoquinolin-7-yl)amino)-2oxoethoxy)acetamide (34). In a hydrogenation flask, 32 (1 eq, 0.165 g, 0.0002441 mol) was dissolved
in 15 mL MeOH. To this solution, 10% Pd/C (0.0165 g, 10% w/w) was added. The flask was placed on
a hydrogenator at 60 psi using H2 gas for 24 hours and monitored by TLC (7:1:0.01
DCM:MeOH:NH4OH). Once completed, the reaction mixture was filtered and then evaporated to
dryness to give 0.086 g 34 at 67% yield. 1H NMR (400 MHz, MeOD) δ 0.153 (s, 2H), 0.526 (m, 2H),
0.547 (s, 1H), 1.387 (m, 4H), 1.616 (m, 6H), 1.923 (m, 1H), 2.161 (m, 1H), 2.219 (m, 1H), 2.396 (m,
2H), 2.624 (m, 2H), 2.736 (t, J = 6.4 Hz, 2H), 3.106 (m, 2H), 3.315 (s, 2H), 3.771 (m, 1H), 4.068 (s,
4H), 4.504 (d, J = 7.6 Hz, 1H), 6.560 (d, J = 7.6 Hz, 1H), 6.643 (d, J = 7.6 Hz, 1H).
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35

N-(9-aminononyl)-2-(2-(((4R, 4aS, 7R, 7aR, 12bS)-3-(cyclopropylmethyl)-4a,9-dihyroxy2,3,4,4a,5,6,7,7a-octahydro-1H-4,12-methanobenzofuro[3,2-e]isoquinolin-7-yl)amino)-2oxoethoxy)acetamide (35) In a hydrogenation flask, 33 (1 eq, 0.160 g, 0.0002186 mol) was dissolved in
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15 mL MeOH. To this solution, 10% Pd/C (0.0160 g, 10% w/w) was added. The flask was placed on a
hydrogenator at 60 psi using H2 gas for 24 hours and monitored by TLC (7:1:0.01
DCM:MeOH:NH4OH). Once completed, the reaction mixture was filtered and then evaporated to
dryness to give 0.091 g 35 at 72% yield. 1H NMR (400 MHz, MeOD) δ 0.171 (m, 2H), 0.534 (d, J =
7.6 Hz, 2H), 0.879 (m, 1H), 0.896 (m, 12H), 1.357 (m, 6H), 1.576 (m, 1H), 2.436 (m, 2H), 2.676 (m,
2H), 2.839 (t, J = 3.5 Hz, 1H), 3.119 (m, 2H), 3.346 (s, 2H), 3.749 (m, 1H), 4.110 (s, 4H), 4.517 (d, J =
7.6 Hz, 1H), 5.481 (s, 4H), 6.628 (m, 2H), 7.352 (m, 1H).

Final Compounds
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5-carbon opioid monovalent compound (22). Methycarbamoylmethoxy acetic acid (1 eq, 0.024 g,
0.0001622 mol) was dissolved with 1 mL DMF in a 5 mL flask. To the solution, 1hydroxybenzotriazole hydrate (1.5 eq, 0.031 g, 0.0002296 mol), triethylamine (6 eq, 0.061 g,
0.0006040 mol) and molecular sieves were added and the reaction was placed under N2 protection
above an ice-water bath at 0 oC. N-(3-dimethylaminopropyl)-N'-ethylcarbodiimide hydrochloride (1.5
eq, 0.035 g, 0.0002258 mol) was added and the water bath was removed, thus allowing the reaction to
return to RT. 34 (1 eq, 0.086 g, 0.0001632 mol) was dissolved in 1 mL DMF and added to the reaction
dropwise. The reaction was monitored with TLC (7:1:0.01 DCM:MeOH:NH4OH) every 24 hours until
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completion and then filtered and evaporated to dryness. Column chromatography was conducted on the
crude product (10:1:0.01 DCM:MeOH, NH4OH) to obtain 0.030 g of 22 at a yield of 30%. 1H NMR
(400 MHz, MeOD) δ 0.525 (s, 2H), 0.747 (m, 2H), 1.119 (s, 1H), 1.404 (brs, 2H), 1.670 (m, 8H), 2.019
(m, 1H), 2.549 (m, 2H), 2.716 (s, 4H), 2.882 (m, 2H), 3.117 (m, 2H), 3.269 (m, 4H), 3.721 (s, 1H),
4.042 (s, 4H), 4.080 (s, 4H), 4.715 (d, J = 7.6 Hz, 2H), 6.747 (s, 2H). 13C NMR (400 MHz, MeOD) δ
3.48, 6.25, 6.90, 24.55, 24.67, 25.21, 25.95, 28.94, 30.05, 31.18, 39.92, 39.97, 47.62, 54.41, 58.87,
64.40, 71.39, 71.50, 71.64, 91.89, 119.72, 121.02, 121.85, 130.75, 143.15, 143.80, 171.75. IR (ATR,
cm-1) vmax: 3274, 2933, 1644, 1549, 1530, 1455, 1373, 1323, 1185, 1124, 1034, 986, 917, 881, 856, 799.
MS (ESI) m/z found, 672 (M + H)+, mp: 115 – 118 oC.
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9-carbon opioid monovalent compound (23). Methycarbamoylmethoxy acetic acid (1 eq, 0.023 g,
0.0001554 mol) was dissolved with 1 mL DMF in a 5 mL flask. To the solution, 1hydroxybenzotriazole hydrate (1.5 eq, 0.032 g, 0.0002370 mol), triethylamine (6 eq, 0.065 g,
0.0006435mol) and molecular sieves were added and the reaction was placed under N2 protection above
an ice-water bath at 0 oC. N-(3-dimethylaminopropyl)-N'-ethylcarbodiimide hydrochloride (1.5 eq,
0.037 g, 0.0002387 mol) was added and the water bath was removed, thus allowing the reaction to
return to RT. 35 (1 eq, 0.091 g, 0.0001560 mol) was dissolved in 1 mL DMF and added to the reaction
dropwise. The reaction was monitored with TLC (7:1:0.01 DCM:MeOH:NH4OH) every 24 hours until
completion and then filtered and evaporated to dryness. Column chromatography was conducted on the
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crude product (10:1:0.01 DCM:MeOH, NH4OH) to obtain 0.030 g 23 at a yield of 25%. 1H NMR (400
MHz, MeOD) δ 0.227 (s, 2H), 0.600 (m, 2H), 0.927 (s, 1H), 1.339 (brs, 10H), 1.536 (m, 8H), 1.940 (m,
1H), 2.292 (s, 2H), 2.443 (s, 2H), 2.816 (m, 5H), 3.118 (m, 2H), 3.298 (m, 4H), 3.7501 (m, 1H), 4.027
(s, 4H), 4.071 (d, J = 4.4 Hz, 4H), 4.801 (d, J = 7.6 Hz, 1H), 6.610 (d, J = 7.6 Hz, 1H), 6.665 (d, J =
7.6 Hz, 1H). 13C NMR (400 MHz, MeOD) δ 4.06, 4.80, 23.74, 25.30, 25.89, 27.90, 27.92, 27.96, 30.26,
30.42, 30.44, 30.48, 31.23, 40.08, 40.11, 52.49, 60.01, 60.04, 63.89, 71.40, 71.44, 71.50, 71.53, 71.56,
71.58, 71.66, 92.73, 118.78, 120.27, 124.89, 132.06, 142.15, 143.75, 171.49, 171.51, 171.57, 172.17.
IR (ATR, cm-1) vmax: 3273, 3078, 2926, 2853, 1651, 1548, 1503, 1454, 1374, 1322, 1258, 1185, 1126,
1035, 987, 916, 883, 857, 799, 747, 699. MS (ESI) m/z found, 728 (M + H)+, mp: 112 – 115 oC.

5.2 Biology Methods
5.2.1 hMOR Competitive Radioligand Binding Assay
The affinity and selectivity of the novel bivalent compounds and their controls were determined
using a competitive radioligand binding assay. In this assay, the concentration of radioligand (i.e.,
tritiated naloxone) was fixed around its Kd value and its binding with respect to hMOR was tested by
adding varying concentrations of drugs. The IC50 values of the bivalents and controls were obtained
from Hill plots and analyzed by linear regression. The Ki values were calculated from the IC50 using the
Cheng-Prusoff equation.
The assay was performed in triplicates with a fixed protein concentration of 30 µg. The total
assay volume was 500 µL with TME buffer. Each assay rack included total binding, non-specific
binding and drug-competition binding tubes. The total binding tubes contained the buffer, radioligand
and protein. The non-specific binding tubes included all of the total binding components as well as
excess unlabeled drug. A maximum of two drugs were tested at seven different concentrations per
rack. These tubes contained the buffer, bivalents (or controls), radioligand and protein. Of note, the
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drug concentration is each tube was multiplied by ten times in order to take the ten-fold dilution in each
tube into account. After the first assay, the drug concentrations were optimized in order to get better
IC50 values. It is also important to note that protein-bound tritiated radioligand was separated from
unbound radioligand by a specialized type of fibrous filter paper, and the radioactive decay of the
unbound radioligand was measured using a scintillation counter.

5.2.2 Calcium Mobilization Assays
5.2.2.1 hMOR-CHO Cells
hMOR-CHO cells were transfected with Gqi5 pcDNA1 and incubated for 6 hours at 37oC and
5% CO2. After the 6-hour interval, the cells were detached from the plate with trypsin and transferred
to a clear bottom, black 96-well plate at 20,000 cells per well. The cells were supplemented with
DMEM/F-12 media containing 5% fetal bovine serum, 100 µg/mL penicillin, 100 µg/mL streptomycin
and 0.25 mg/mL hygromycin B. 24 hours after the transfection the growth media was discarded and
the wells were washed with 100 µL/well of 50:1 HBSS:HEPES assay buffer. The cells were then
incubated with 55 µL/well of Fluo-4 loading buffer [30 µL 2 µM Fluo4-AM and 84 µL 2.5 mM
probenacid in 5.5 mL assay buffer] for 30 minutes. Varying concentration (in triplicate) of ligands and
controls were added to the wells to bring the total volume to 80 µL/well, and the well-plate was again
incubated, this time for 15 minutes. The plate was then read on a FlexStation3 microplate reader
(Molecular Devices) at 494/516 ex/em for a total of 2 minutes. After 15 second of reading, 20 µL of
1.25 µM DAMGO in assay buffer, or assay buffer alone for the control wells, was added to bring the
total volume of each well up to 100 µL. The changes in Ca2+ mobilization were monitored using
SoftMaxPro software. Non-linear regression curves and IC50 values were generated using GraphPad
Prism software. This experiment was performed three times to get an average of each IC50 value.
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5.2.2.2 CCR5-MOLT-4 Cells
CCR5-MOLT-4 cells were transfected with Gqi5 pcDNA1 and maintained in RPMI 1640 media
supplemented with 10% fetal bovine serum, 100 µg/mL penicillin, 100 µg/mL streptomycin and 1
mg/mL G418 before being incubated for 48 hours at 37oC and 5% CO2. 48 hours after the
transfection, the 2.5 million cells were spun down and diluted in 8 mL of 50:1 HBSS:HEPES assay
buffer. The cells were then plated at 25,000 cells per well (80 µL of diluted cell solution) into a clear
bottom, black 96-well plate. Then, 50 µL/well of Fluo-4 loading buffer [40 µL 2 µM Fluo4-AM and
100 µL 2.5 mM probenacid in 5 mL assay buffer] was added to bring the volume of each well up to 130
µL. The plate was incubated for 45 minutes, after which varying concentrations (in triplicate) of
ligands and controls were added to the wells to bring the total volume up to 180 µL. The plate was
then incubated for an additional 15 minutes. The plate was then read on a FlexStation3 microplate
reader (Molecular Devices) at 494/516 ex/em for a total of 1.5 minutes. After 15 second of reading, 20
µL of 200 nM RANTES in assay buffer, or assay buffer alone for the control wells, was added to bring
the total volume of each well up to 200 µL. The changes in Ca2+ mobilization were monitored using
SoftMaxPro software. Non-linear regression curves and IC50 values were generated using GraphPad
Prism software. This experiment was performed three times to get an average of each IC50 value.

5.3 Computational Methods

5.3.1 Small Molecule Construction
All ligands used in the conformational analysis studies were built with standard bonds and
angles using the molecular modeling software SYBYL-X 2.0. The proper stereochemical arrangements
were also assigned for each asymmetric carbon to ensure viability of results and uniform spatial
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arrangements between each spacer molecule. For the process of energy minimization (to establish a
local minimum conformation for each small molecule), each small molecule was assigned GasteigerHuckel charges and then minimized using the Tripos Force Field.

5.3.2 Global Minimization Conformational Analysis
The molecules were first drawn in the SYBYL-X 2.0 molecular modeling program and then,
after assigning them Gasteiger-Huckel charges, minimized using the Tripos Force Field. The
parameters for the global minimization conformational analysis studies were then set up using Confort
conformational analysis modeling software, a program developed by Professor Robert Pearlman and
Dr. Renzo Balducci.128 For the global minimization of each small molecule, the search options were
optimized to give accurate and viable results. First, the search was set to include the conformations of
all rotatable bonds. Then, the maximum number of concurrently searched rotors was set to 100 for
acyclic bonds, 20 for bonds included in ring systems and 10 for bonds in single rings (these parameters
were required to ensure accuracy of results). Gasteiger-Huckel electrostatics were assigned to each
molecule and the precision of results was set to .001 kcal/mol. The maximum output of low energy
conformers was set to 10 in order to produce a global minimum and 9 low-energy conformers within
approximately 10 kcal/mol of the global minimum. The program was then run and the results were put
into a SYBYL spreadsheet, organizing each conformer by energy relative to the global minimum.
After each of the conformers were analyzed, the global minimum conformer was placed into the
SYBYL molecular area and a snapshot of it was taken.

5.3.3 Diverse Conformer Subset Conformational Analysis
The molecules were first drawn in the SYBYL-x 2.0 molecular modeling software and then
minimized using the Tripos Force Field. Each molecule was assigned Gasteiger-Huckel charges before
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energy minimization. The parameters for the diverse conformer subset conformational analysis studies
were then set up using Confort conformational analysis software.128 In developing a diverse conformer
subset for each molecule, the search options were optimized to give repeatable, accurate and viable
results. Like in the global minimization conformational analysis studies, the search was set to include
all conformations of rotatable bonds. The maximum number of concurrently searched rotors was set to
100 for acyclic bonds, 20 for bonds included in ring systems and 10 for bonds in single rings. Again,
these parameters were required to produce accurate results. Gasteiger-Huckel electrostatics were
assigned to each molecule and the precision of results was set to .001 kcal/mol. Also included in the
search options was a maximum conformer output of 500 low-energy conformations. The output
settings were further modified to include a maximum of 500 diverse low-energy conformers (i.e., any
conformer nearly identical in spatial arrangement and energy to another already-produced conformer
would be rejected from the search results) within at least 100 kcal/mol of the lowest-energy conformer.
The program was then run and the results were put into a SYBYL spreadsheet, organizing each
conformer by energy relative to the lowest-energy conformer. A subset of 10 low-energy conformers
within 20 – 30 conformers of the lowest-energy conformer were then extracted from the spreadsheet
and placed into the SYBYL molecular area. These 10 conformers were aligned according to specific
atoms within the molecule to give a comparative analysis. Once this was completed, a snapshot of the
superimposed molecules was taken.
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